Evotec and Celmatix enter strategic partnership
Evotec SE has expanded its drug discovery customer base with US women’s health specialist Celmatix Inc.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
Qiagen/Illumina: Earthquake in NGS IVD market
QIAGEN and Illumina join forces in the next-gen sequencing-based IVD testing and companion diagnostics market announcing a 15-year collaboration.
Long-term stabilization of assay components
Many users in research labs like to store their assay components such as assay antibodies, conjugates, antigens, calibrators or coated ELISA plates for a while without losing functionality.
Researchers unravel how ADEP antibiotics work
German researchers have determined the mechanism of a ADEPs, a novel class of antibiotics, allowing for pharmacological optimisation.
New method allows tracking of HIV
A new method allows real-time-visualisation of how the HI virus spreads between living T helper cells and which molecules it requires for this purpose.
Successful EFIB in Brussels
How can biotechnology and bioeconomy contribute to establish a sustainable and circular economy? Nearly 500 attendees discussed latest trends at EFIB 2019 in Brussels.
Rottapharm Biotech: POC in osteoarthritis pain
Rottapharm Biotech (Monza, Italy) has published detailed results from a clinical Phase II trial of CR4056 in chronic pain from knee osteoarthritis.
Spanish sector attracting more and more investment
Spain’s biotech association Asebio announced new record numbers from its biotech investor day held as part of the European Biotech Week.
Creoptix AG closes CHF8m financing round
Swiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion.
AMR: GARDP and Entasis Therapeutics start pivotal study
Entasis Therapeutics Inc (Waltham, USA) and non for profit organisation GARDP (Geneva, Switzerland) have initiated Phase III testing of the novel antibiotic zoliflodacin to treat infections with the WHO priority pathogen N. gonorrhoea.